Resistance of Animal Strains of Pseudomonas aeruginosa to Carbapenems. 2017

Marisa Haenni, and Maxime Bour, and Pierre Châtre, and Jean-Yves Madec, and Patrick Plésiat, and Katy Jeannot
Unité Antibiorésistance et Virulence Bactériennes, ANSES-Université de LyonLyon, France.

Carbapenems are major antibiotics reserved to human medicine. This study aimed to investigate the mechanisms of carbapenem resistance of a selection of Pseudomonas aeruginosa veterinary strains from the French network Resapath. Thirty (5.7%) imipenem and/or meropenem non-susceptible P. aeruginosa of canine (n = 24), feline (n = 5), or bovine (n = 1) origin were identified in a large collection of 527 veterinary strains gathered by the Resapath. These resistant isolates belonged to 25 MultiLocus Sequence Types (MLST), of which 17 (68%) are shared with clinical (human) strains, such as high risk clones ST233 and ST395. Interestingly, none of the veterinary strains produced a carbapenemase, and only six of them (20%) harbored deletions or insertion sequence (IS) disrupting the porin OprD gene. The remaining 24 strains contained mutations or IS in various loci resulting in down-regulation of gene oprD coupled with upregulation of efflux system CzcCBA (n = 3; activation of sensor kinase CzcS ± CopS), MexEF-OprN (n = 4; alteration of oxido reductase MexS), MexXY (n = 8; activation of two-component system ParRS), or MexAB-OprM (n = 12; alteration of regulator MexR, NalC ± NalD). Two efflux pumps were co-produced simultaneously in three mutants. Finally, in 11 out of 12 strains displaying an intact porin OprD, derepression of MexAB-OprM accounted for a decreased susceptibility to meropenem relative to imipenem. Though not treated by carbapenems, animals thus represent a reservoir of multidrug resistant P. aeruginosa strains potentially able to contaminate fragile outpatients.

UI MeSH Term Description Entries

Related Publications

Marisa Haenni, and Maxime Bour, and Pierre Châtre, and Jean-Yves Madec, and Patrick Plésiat, and Katy Jeannot
April 1999, Journal of chemotherapy (Florence, Italy),
Marisa Haenni, and Maxime Bour, and Pierre Châtre, and Jean-Yves Madec, and Patrick Plésiat, and Katy Jeannot
January 2018, Journal of infection in developing countries,
Marisa Haenni, and Maxime Bour, and Pierre Châtre, and Jean-Yves Madec, and Patrick Plésiat, and Katy Jeannot
October 2009, Transplantation proceedings,
Marisa Haenni, and Maxime Bour, and Pierre Châtre, and Jean-Yves Madec, and Patrick Plésiat, and Katy Jeannot
March 2018, International journal of antimicrobial agents,
Marisa Haenni, and Maxime Bour, and Pierre Châtre, and Jean-Yves Madec, and Patrick Plésiat, and Katy Jeannot
October 1991, Nihon rinsho. Japanese journal of clinical medicine,
Marisa Haenni, and Maxime Bour, and Pierre Châtre, and Jean-Yves Madec, and Patrick Plésiat, and Katy Jeannot
February 2014, Zhonghua shao shang za zhi = Zhonghua shaoshang zazhi = Chinese journal of burns,
Marisa Haenni, and Maxime Bour, and Pierre Châtre, and Jean-Yves Madec, and Patrick Plésiat, and Katy Jeannot
August 1995, The Journal of antibiotics,
Marisa Haenni, and Maxime Bour, and Pierre Châtre, and Jean-Yves Madec, and Patrick Plésiat, and Katy Jeannot
September 2003, Antimicrobial agents and chemotherapy,
Marisa Haenni, and Maxime Bour, and Pierre Châtre, and Jean-Yves Madec, and Patrick Plésiat, and Katy Jeannot
June 2010, Antimicrobial agents and chemotherapy,
Marisa Haenni, and Maxime Bour, and Pierre Châtre, and Jean-Yves Madec, and Patrick Plésiat, and Katy Jeannot
August 2011, Journal of chemotherapy (Florence, Italy),
Copied contents to your clipboard!